Opposing mechanisms of stabilizing and destabilizing receptors. The control of barrier integrity in the vascular endothelium is central to medicine. In essence the classic signs of inflammation (rubor, calor, dolor, tumor) are products of a destabilized barrier. The main premise of this grant application is that there are competing ligand-receptors that signal through converging pathways that determine the level of stability/instability of the endothelial barrier. Specifically, we will study the stabilizing and destabilizing influences on the endothelial barrier of, respectively, the Robo1 receptor and the receptor for interleukin-1b (IL1R). We hypothesize that the opposing signals from these receptors are due to the activation of opposing GTPase activating proteins (GAP) and guanine nucleotide exchange factors (GEF) that determine, respectively, the inactive and active state of ARF6 and the strength of cell-cell interactions. We suspect that the mechanistic insights derived in our studies will have broad implications to barrier function and cell-cell interactions in many tissues. Our work will suggest for the first time that it may be possible to uncouple the ability o cytokines to disrupt tissue barriers from their stimulation of transcriptional immunomodulatory pathways.
Opposing mechanisms of stabilizing and destabilizing receptors. In any inflammatory condition from arthritis to eye disease a central issue is the integrity of the blood vessel walls. Inflammatory cytokines or proteins compromise the vessel wall allowing fluid and cells traveling within the blood vessel to seep into tissues. We will understand how these cytokines disrupt the vascular barrier and initiate tissue swelling and destruction, and how other proteins seek to stabilize the vascular wall. Our studies have a direct application to medicine as it reveals a new pathway that if blocked by a pharmaceutical will reduce tissue disruption and destruction in animal models of inflammation and arthritis.
|Yoo, Jae Hyuk; Shi, Dallas S; Grossmann, Allie H et al. (2016) ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell 29:889-904|
|Zhao, Helong; Ahirwar, Dinesh K; Oghumu, Steve et al. (2016) Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. Mol Oncol 10:272-81|
|Zhou, Zinan; Tang, Alan T; Wong, Weng-Yew et al. (2016) Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature 532:122-6|
|Gibson, Christopher C; Zhu, Weiquan; Davis, Chadwick T et al. (2015) Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation 131:289-99|
|Qi, Qi; Li, Dean Y; Luo, Hongbo R et al. (2015) Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. Proc Natl Acad Sci U S A 112:7255-60|
|Yu, Jinlong; Zhang, Xuefeng; Kuzontkoski, Paula M et al. (2014) Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway. Cell Commun Signal 12:25|
|Shi, Dallas S; Smith, Matthew C P; Campbell, Robert A et al. (2014) Proteasome function is required for platelet production. J Clin Invest 124:3757-66|
|Grossmann, Allie H; Yoo, Jae Hyuk; Clancy, James et al. (2013) The small GTPase ARF6 stimulates Î²-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal 6:ra14|
|Luo, Ling; Uehara, Hironori; Zhang, Xiaohui et al. (2013) Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife 2:e00324|
|Sawada, Junko; Urakami, Takeo; Li, Fangfei et al. (2012) Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 22:235-49|
Showing the most recent 10 out of 27 publications